Analysts are offering their two cents on biotech firms Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP).
After Amicus Therapeutics, Inc. (NASDAQ:FOLD) met with the FDA and received written minutes, the biotech firm revealed yesterday that with the present data …
Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares jumped over 20% today after the drug maker released its third-quarter results, posting EPS of $(0.
Celator Pharmaceuticals Inc (NASDAQ:CPXX) is up an overwhelming 71% to $30.12 in pre-market trading following this morning’s announcement that the company will be …
In a research report released today, Cowen’s healthcare analyst Ritu Baral reiterated an Outperform rating on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD), and raised the price …
Amicus Therapeutics, Inc. (NASDAQ:FOLD), long implicated as an acquisition target by its investors, will do some acquiring of its own.
In a research report issued today, Chardan Capital analyst Gbola Amusa initiated coverage on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) with a Buy rating …
In a research report issued today, Cowen analyst Ritu Baral reiterated an Outperform rating on Amicus Therapeutics (NASDAQ:FOLD) with a $14 price target, following …
Amicus Therapeutics (FOLD) today announced robust 18-month data from the migalastat monotherapy Study 012 in Fabry patients with amenable mutations. Migalastat met the …
In a research note published August 8, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Amicus Therapeutics (FOLD) with a $5 …
